Sangamo BioSciences | SGMO - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Alaunos Therapeutics USD 1.19M 148K 2025-09
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Alterity Therapeutics Limited AUD 7.78M 3M 2023-06
Amgen USD 5.9B 773M 2025-12
Bayer EUR 10.33B 126M 2025-12
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Cipla INR 60.98B 1.06B 2025-12
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.29M 1.51M 2025-12
CSL USD 5.7B 2.82B 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Grifols EUR 1.99B 217.4M 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
J&J USD 18.97B 2.38B 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Merck USD 10.16B 558M 2025-12
Novartis USD 9.8B 61M 2025-12
Omeros USD 59.16M 20.13M 2024-06
Pfizer USD 12.91B 79.89B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 10.51B 1.21B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Tectonic Therapeutic USD 21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12